HQY vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HQY presents a stark divergence between strong fundamental earnings performance and bearish market sentiment. The company maintains a stable financial health profile with a Piotroski F-Score of 4/9 and excellent liquidity (Current Ratio 3.27). While the current price of $77.96 trades at a premium to its intrinsic value ($72.57) and Graham Number ($37.04), the Forward P/E of 14.60 suggests significant expected earnings expansion. However, the bullish fundamental outlook is heavily countered by a 0/100 technical trend and consistent insider selling.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
HQY vs LLY: Head-to-Head Comparison
This page compares HealthEquity, Inc. (HQY) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.